期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Application of Fusobacterium nucleatum as a biomarker in gastrointestinal malignancies
1
作者 Long-Chen Yu Ya-Ping Li +6 位作者 Yue-Ming Xin mai mao Ya-Xin Pan Yi-Xuan Qu Zheng-Dong Luo Yi Zhang Xin Zhang 《World Journal of Gastrointestinal Oncology》 SCIE 2024年第6期2271-2283,共13页
The morbidity and mortality of gastrointestinal(GI)malignancies are among the highest in the world,posing a serious threat to human health.Because of the insidious onset of the cancer,it is difficult for patients to b... The morbidity and mortality of gastrointestinal(GI)malignancies are among the highest in the world,posing a serious threat to human health.Because of the insidious onset of the cancer,it is difficult for patients to be diagnosed at an early stage,and it rapidly progresses to an advanced stage,resulting in poor treatment and prognosis.Fusobacterium nucleatum(F.nucleatum)is a gram-negative,sporefree anaerobic bacterium that primarily colonizes the oral cavity and is implicated in the development of colorectal,esophageal,gastric,and pancreatic cancers via various intricate mechanisms.Recent development in novel research suggests that F.nucleatum may function as a biomarker in GI malignancies.Detecting the abundance of F.nucleatum in stool,saliva,and serum samples of patients may aid in the diagnosis,risk assessment,and prognosis monitoring of GI malignancies.This editorial systematically describes the biological roles and mechanisms of F.nucleatum in GI malignancies focusing on the application of F.nucleatum as a biomarker in the diagnosis and prognosis of GI malignancies to promote the clinical translation of F.nucleatum and GI tumors-related research. 展开更多
关键词 Gastrointestinal malignancies Fusobacterium nucleatum BIOMARKER Diagnosis PROGNOSIS
下载PDF
血清肿瘤标志物水平评价晚期非小细胞肺癌靶向治疗价值研究 被引量:10
2
作者 孙钦文 梁蓝月 +2 位作者 孙成晖 麦茂 严伟红 《中国医药科学》 2018年第11期184-187,共4页
目的探究血清肿瘤标志物水平评价晚期非小细胞肺癌靶向治疗价值。方法选自本院2016年3月~2017年3月经晚期非小细胞肺癌靶向治疗的80例患者,所有患者均实施靶向治疗,观察患者治疗前及治疗后各项血清肿瘤标志物水平情况。结果 80例患者治... 目的探究血清肿瘤标志物水平评价晚期非小细胞肺癌靶向治疗价值。方法选自本院2016年3月~2017年3月经晚期非小细胞肺癌靶向治疗的80例患者,所有患者均实施靶向治疗,观察患者治疗前及治疗后各项血清肿瘤标志物水平情况。结果 80例患者治疗有效例数为39例(48.75%),无效为41例(51.25%)。按照治疗效果分为有效组与无效组。两组治疗前各项血清肿瘤标志物水平比较差异无统计学意义(P>0.05);治疗后,有效组各项血清肿瘤标志物水平优于无效组(P<0.05)。不同病理类型晚期NSCLC肿瘤标志物血清水平比较差异有统计学意义(P<0.05);而CEA、CA125水平依次从腺癌、腺鳞癌及鳞癌减低,SCC、CYFAR21-1依次从腺癌、腺鳞癌及鳞癌升高。单项肿瘤标志物检测的敏感度、特异度与准确度中,CA125敏感度及准确度最高、特异度最低,而CEA特异度最高。结论血清肿瘤标志物水平可有效评价晚期非小细胞肺癌靶向治疗的临床疗效。 展开更多
关键词 非小细胞肺癌 靶向治疗 血清肿瘤标志物水平 敏感度 准确度
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部